Last Updated : September 6, 2024
Details
Generic Name:
blinatumomab
Project Status:
Pending
Therapeutic Area:
B-cell precursor acute lymphoblastic leukemia
Manufacturer:
Amgen Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0365-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For
the treatment of patients with Philadelphia chromosome-negative CD19 positive B-cell precursor
acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy.
Fee Schedule:
Pending
Indications:
For
the treatment of patients with Philadelphia chromosome-negative CD19 positive B-cell precursor
acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : September 6, 2024